The Institute for Biomathematics and Biometry conducts fundamental research in areas including Epidemiology, Analysis of Complex Experimental Data, Analysis of Environmental Chemicals, Machine Learning, Bacterial Communication Processes in the Rhizosphere, the Regulation Pathway of NF-κB and Coagulation Cascades.

Shanghai Longyao Biotech Co., Ltd. engages in the provision of health management services. It focuses on the innovative and development of biotechnology such as tumor immune cell technology,\nstem cell technology, cell storage technology, and anti-aging technology. Its business scope includes\ntechnology development, technical consulting, technology transfer, and technical services of biotechnology; and import and export of goods and technology. The company was founded on September 16, 2013 and is headquartered in Shanghai, China.,

Guangzhou Andisheng Biomedical Technology Co., Ltd., established on 2017-04-17, Business scope includes research in health science projects,to develop;Stem Cell Technology Research,to develop;Medical Research and Experimental Development;Biomedical Technology Research;Regenerative Medicine Anti-aging Research Services;Medical technology research and development;drug development;Gene drug development;Stem Cell Drug Development;Research and development of biodiagnostic reagents and kits(Does not include license approval items);Biotechnology Extension Services;Biotechnology Development Services;Biotechnology Consulting,communication service;Biotechnology Transfer Services;Human Science Research Achievement Transfer Service;Medical technology promotion service;Medical Technology Consulting,communication service;Medical technology transfer service;

Hebei Senlang Biotechnology is focused on the treatment of immune cells new technology development and application of high-tech enterprises.The company has the CAR-T research base (Senrang CAR-T Research Center) in North China, and has formed a high-barrier technology platform such as innovative CAR structural design, virus and cell culture , which can take into account technical research and development, hospital clinical application Provide high-quality and effective cellular immunotherapy support for hematological tumors, solid tumors and other tumor diseases, immune system diseases and other patients.

Qingdao Medisys Biotechnology Co., Ltd., established on 2012-08-15, Business scope includes import and export of goods,Technology Import and Export(Except for items prohibited by laws and administrative regulations,Projects restricted by laws and administrative regulations will be operated after obtaining permission),Biotechnology R&D,Technical Consulting and Technical Services,Wholesale and retail:chemical reagent(Free of Hazardous Chemicals),laboratory consumables,equipment,Office Supplies,Computer hardware and software and accessories,electronic product,Photographic camera equipment,communication equipment(Does not include radio transmission and ground satellite reception equipment),electronics,Wujinjiaodian,medical instruments,R&D of cosmetics,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Guangzhou Saliai Stemcell Science & Technology Co., Ltd. engages in the provision of stem cell storage, health supplements, biological products, and related health management services. It involves in the production of regenerative medicine devices, medical nutrition supplements, and biological & medical cosmetic products. It operates a research and development platform which includes life bank, health management center, medical center, and medical cell center. The company was founded by Hai Jia Chen and Ming Jia Chen on July 7, 2009 and is headquartered in Guangzhou, China.

The Life Ark is focusing on the storage and application of immune cells and integrates R&D, production, and marketing. The company is a core API manufacturer of innovative cell drugs , mainly engaged in the development of large-scale preparation reagents for immune cells, especially NK cells in vitro. As one of the earliest immune cell research companies in China, Zhongying Bio has 35 invention patents , and has ensured its leading position in the industry with advanced technology.

Vaxcell-Bio Therapeutics develops anti-cancer therapeutics. It specializes in immune cell therapy. The company was founded by Lee Jae-Jung on February 18, 2010 and is headquartered in Hwasun-gun, South Korea.

Shanghai Collison Biotechnology Co., Ltd., established on 2007-10-10, Business scope includes technology development in the field of biotechnology,technical consulting,Technical Services,technology transfer,Drug Discovery,laboratory reagent(In addition to dangerous goods),laboratory consumables,Pharmaceutical Intermediates(In addition to drugs),Chemical raw materials(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals)promotion of,investment management,Business Information Consulting Service(In addition to brokerage),Hospital Investment Management,Medical device management. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Basilea Pharmaceutica China Ltd., part of Basilea Pharmaceutica AG, is a company headquartered in Nantong, China. The firm engages in research, development and commercialization of anti-infective and anti-cancer drugs. It was founded in 2002. You Zhou is currently the CEO of the company.\nThe company says this about itself: Basilea Pharmaceutica China Ltd. (BPC) was founded in 2002 and is located in the Haimen Economic-Technological Development Zone of Nantong city, Jiangsu, a ninety minutes’ drive from Shanghai. Operating in an innovative R&D environment, the company builds on its highly qualified, well-trained and experienced professionals as well as a state-of-the-art scientific and technical infrastructure. BPC focuses on the chemical synthesis and analysis of complex molecules, analytical development and process research and development, so as to provide R&D services to worldwide customers.

Shanghai Shangyao Ruier Pharmaceutical Co., Ltd., established on 2020-12-29, Business scope includes licensed projects:Class III medical device business;pharmaceutical production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:drug development;Biological product,food,Biological reagents for non-clinical diagnosis,medical instruments,cosmetic,Medical Technology,Technology development in the field of new material technology,technical consulting,technology transfer,Technology Exchange,Technical Services,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Medical equipment rental;Conference and Exhibition Services;Cosmetics Wholesale;Import and export;Technology Import and Export;Import and export agency.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shanghai Public Health Clinical Center is a Chinese company located in Shanghai and ultimately controlled by the Government of China that operates hospital and provides education and training for disease control and prevention.

Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors. The company's therapy specializes in developing virus specific T-cells and CAR T cells for the treatment of lymphoma, enabling healthcare providers to treat cancer patients and improve their lives.

Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises. At present, the company focuses on the development and manufacturing of macromolecular drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins. There are more than thirty varieties of drugs at different stages of development covering tumor, autoimmunity, anti-infection and ophthalmic diseases. Among them, six of them have entered the clinical stage, and three of them are in Phase III clinical trials.

Shandong Desheng Biological Engineering Co., Ltd., established on 2019-01-18, Business scope includes bioengineering;tissue storage;cell engineering;medicine,Biotechnology,stem cell,Immune Cells,Research and development of cell expansion technology;Production of Medical Devices,wholesale,retail;cosmetic,daily necessities,Health food technology development and sales;Pre-packaged food,medicine,Packaging Materials,Instrumentation,glassware,electronic product,Hotel Supplies,Laboratory equipment and consumables,test reagent(Free of Hazardous Chemicals)Wholesale,retail;Warehousing Services(Free of Hazardous Chemicals);General cargo road transport;Import and export of goods and technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval);Domestic trade agent;genetic engineering and other legal,regulations,Items that are not prohibited by the State Council's decision and do not require a business license(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

IPMBiotech focuses on the development and application of precision medical technology and cell therapy technology.

Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., established on 2014-03-26, Business scope includes biological,Pharmaceutical technology development,technology transfer,technical consulting,Technical Services;Sales of biological reagents(Free of Hazardous Chemicals,medicine).(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Beijing Aokanghua Medical Laboratory Co., Ltd., established on 2015-11-02, Business scope includes medical laboratory services(clinical immunization,Serology major;Clinical Cytomolecular Genetics Major);health management,Health Advisory(Except for medical treatment activities subject to approval);technology development;Technology Promotion;technology transfer;technical consulting;Technical Services;Medical Research and Experimental Development;Sales instrumentation,Chemical Products(Does not contain dangerous chemicals and a class of precursor chemicals),cosmetic,hygiene products,one type,Class II medical device;Machinery and Equipment Leasing.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.